Showing 261 - 280 results of 108,445 for search '(( a point decrease ) OR ( 5 ((((wt decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 1.74s Refine Results
  1. 261

    Prevalence reduction of overall obesity in 2022–2027, according to a decrease in the probability of move up one BMI class and an increase in the probability of move down one BMI cl... by Pierre Bauvin (18154818)

    Published 2024
    “…Scenarios 1 and 2 were built up to obtain a stabilization of the overall obesity prevalence: scenario 1 corresponds to a 22% decrease in the probability of move up one BMI class, and scenario 2 corresponds to a 33% increase in the probability of move down one BMI class. …”
  2. 262

    SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT). by Eduardo Molina-Jijón (4020464)

    Published 2017
    “…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
  3. 263
  4. 264

    Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation. by Arindam P. Ghosh (317870)

    Published 2013
    “…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”
  5. 265
  6. 266
  7. 267
  8. 268
  9. 269
  10. 270
  11. 271
  12. 272
  13. 273
  14. 274
  15. 275

    Eltrombopag markedly decreases levels of ROS in MOLM14 cells. by Anna Kalota (7415)

    Published 2015
    “…B) Graphic presentation of ROS levels measured by flow cytometry in cells treated with E (5 μM) or DPI (25 μM), an inhibitor of NADPH oxidase known to decrease an intracellular level of ROS, or untreated (CTR) cells. …”
  16. 276

    A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

    Published 2018
    “…<b>(C)</b> The mutant CLCuMuV carrying C4<sup>R13A</sup> (CLCuMuV-C4<sup>R13A</sup>), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”
  17. 277
  18. 278
  19. 279
  20. 280